Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.43 |
| ▸ | LSS | P48449 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.36 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.36 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21114046 | 1.00 | NSD2 (0.43) | NSD2NSD3LSSMEN1KMT2A | |
| SCHEMBL21113969 | 0.98 | NSD2 (0.44) | NSD2NSD3LSSMEN1KMT2A | |
| SCHEMBL25299247 | 0.87 | NSD2 (0.46) | NSD2NSD3MAOBSLC6A4KCNH2 | |
| SCHEMBL6396448 | 0.86 | MAOB (0.41) | MAOAALDH2MAOBSLC6A4PRMT1 | |
| SCHEMBL6660968 | 0.85 | NR5A1 (0.50) | CYP2D6HTR2AMAPT | |
| SCHEMBL8751857 | 0.85 | NR5A1 (0.50) | CYP2D6HTR2AMAPT | |
| SCHEMBL8216480 | 0.85 | NR5A1 (0.50) | CYP2D6HTR2AMAPT | |
| SCHEMBL8751856 | 0.85 | NR5A1 (0.50) | CYP2D6HTR2AMAPT | |
| SCHEMBL8731575 | 0.85 | NR5A1 (0.50) | CYP2D6HTR2AMAPT | |
| SCHEMBL9698432 | 0.85 | NR5A1 (0.50) | CYP2D6HTR2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2019-07-11 | — | — | US | disclosed |
| WO-2019136314-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2019-07-11 | — | — | WO | disclosed |
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, SERPINB1 | NSD2 4579/4885NSD3 4606/4885LSS 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.